The issuance of asset-based securities (ABSs) in South Korea fell markedly from a year earlier in 2024 due to a sharp decline ...

SEOUL, Jan. 31 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and ...